Based on these findings, we decided to perform further analysis on a cohort of 1502 consecutive BC patients without metastatic disease and other cancers who underwent surgery in the years 2015–2018, assessing the appropriateness of conventional circulating markers (CEA and CA15-3) 365 days after surgery (Table 1). The gene discussed is CEACAM5; the disease is cancer.